Erastin is a selective antitumor agent that displays greater lethality in human tumor cells harboring mutations in the oncogenes HRAS, KRAS, or BRAF. It binds to mitochondrial voltage-dependent anion channels (VDAC) proteins, more specifically on VDAC2, and alters its gating. Erastin rapidly induces oxidative, non-apoptotic cell death in several human tumors harboring activating mutations in the RAS-RAF-MEK signaling.